A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea
An Open-Label Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 for 40 Weeks in the Treatment of Moderate to Severe Facial Papulopustular Rosacea (Study FX2016-13)
Sponsor: Vyne Therapeutics Inc.
This PHASE3 trial investigates Papulopustular Rosacea and is currently completed. Vyne Therapeutics Inc. leads this study, which shows 12 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Feb 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Oct 2021 — Feb 2022 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE3
-
May 2019 — Mar 2020 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jul 2018 — May 2019 [monthly]
Active Not Recruiting PHASE3
Status: Enrolling By Invitation → Active Not Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Enrolling By Invitation PHASE3
-
Nov 2017 — Jun 2018 [monthly]
Enrolling By Invitation PHASE3
-
Oct 2017 — Nov 2017 [monthly]
Enrolling By Invitation PHASE3
First recorded
Sep 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Vyne Therapeutics Inc.
For direct contact, visit the study record on ClinicalTrials.gov .